NasdaqGS:LEGNBiotechs
Legend Biotech (LEGN) Q1 Loss Persists And Tests Bullish Profitability Narratives
Legend Biotech (LEGN) has reported Q1 2026 revenue of US$305.1 million, with a basic EPS loss of US$0.29 and a net loss of US$54.3 million, setting the tone for a quarter where top line scale contrasts with continued spending. Over recent periods, revenue has moved from US$186.6 million in Q4 2024 to US$195.1 million in Q1 2025 and then to US$305.1 million in Q1 2026. Basic EPS has shifted from a profit of US$0.14 in Q4 2024 to losses of US$0.55 in Q1 2025 and US$0.29 in Q1 2026, leaving...